-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – YTE-001 in Epstein–Barr Virus (HHV-4) Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - YTE-001 in Epstein–Barr Virus (HHV-4) Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. YTE-001 in Epstein–Barr Virus (HHV-4) Infections Drug Details: Gene therapy...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Polatuzumab Vedotin in Primary Mediastinal B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Polatuzumab Vedotin in Primary Mediastinal B-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Polatuzumab Vedotin in Primary Mediastinal B-Cell Lymphoma Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ruxolitinib Phosphate in Hand Dermatitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ruxolitinib Phosphate in Hand Dermatitis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ruxolitinib Phosphate in Hand Dermatitis Drug Details: Ruxolitinib (INCB18424, Jakafi, Jakavi)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Durvalumab in Endometrial Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Durvalumab in Endometrial Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Durvalumab in Endometrial Cancer Drug Details: Durvalumab (MEDI-4736, Imfinzi, Fidursi, Imfinzio)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Durvalumab in Fallopian Tube Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Durvalumab in Fallopian Tube Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Durvalumab in Fallopian Tube Cancer Drug Details: Durvalumab (MEDI-4736, Imfinzi,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Durvalumab in Peritoneal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Durvalumab in Peritoneal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Durvalumab in Peritoneal Cancer Drug Details: Durvalumab (MEDI-4736, Imfinzi, Fidursi, Imfinzio)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Durvalumab in Pancreatic Ductal Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Durvalumab in Pancreatic Ductal Adenocarcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Durvalumab in Pancreatic Ductal Adenocarcinoma Drug Details: Durvalumab (MEDI-4736, Imfinzi,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Apatinib Mesylate in Recurrent Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Apatinib Mesylate in Recurrent Glioblastoma Multiforme (GBM) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Apatinib Mesylate in Recurrent Glioblastoma Multiforme (GBM) Drug...